Ponatinib (PON) is a third-generation BCR-ABL TKI approved by the United States Food and Drug Administration in December 2012 as the second-line treatment of CML and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.